RxDoctor Payments Data

Katherine Crow

Nurse Practitioner · Greenville, SCNPI 1518688621

Payments from drug & device makers

$2,042in general payments, 2019–2025

Across 107 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$523
  • Neurocrine Biosciences, Inc.$415
  • AbbVie$239
  • Acadia Pharmaceuticals Inc$213
  • Acorda Therapeutics, Inc$81
  • Argenx US, Inc.$67
  • plus $505 from 19 others

What the payments were for

  • Food & beverage$1,98897%
  • Education$543%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,042 in reported general payments places this provider in the 85th percentile of 1,346 nurse practitioner providers in South Carolina.

See all nurse practitioner providers in South Carolina

Medicare billing

Part B allowed, 2024
$115,197
Medicare patients
198
Services billed
13,216

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate25$121,958
BotoxOnabotulinumtoxina38$48,964
Nurtec OdtRimegepant Sulfate21$35,950
UbrelvyUbrogepant15$22,037
RytaryCarbidopa/Levodopa11$3,972
Carbidopa-LevodopaCarbidopa/Levodopa135$3,380
Carbidopa-Levodopa ErCarbidopa/Levodopa97$2,853
AmantadineAmantadine Hcl13$562
Memantine Hcl36$502
Donepezil Hcl35$286
Levetiracetam11$200
Sertraline Hcl18$159
Quetiapine Fumarate15$115
Gabapentin11$91

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$213$121,95825 claims
AbbVieBotox, Ubrelvy$239$71,00153 claims
PfizerNurtec Odt$43$35,95021 claims
Amneal Pharmaceuticals LLCRytary$17$3,97211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,346 nurse practitioner providers in South Carolina.

Other nurse practitioner in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →